Bayer : Separation of Consumer Health would be a win-win; execution could be difficult
>Sale of Consumer Health appears the most likely option - In recent months, pressure from activist shareholders to break-up Bayer’s current conglomerate structure has grown steadily. With Bill Anderson taking over as CEO in June 2023 the likelihood has increased that the traditional three-pillar strategy will be put to the test. Bill Anderson has been very vocal from the outset about reviewing the status quo and considering all options for the benefit of employees, cu...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.